Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health, announced that Interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The company is advancing treatments for depression and anxiety, with its lead drug HLP003 in Phase 3 and HLP004 in Phase 2 clinical trials. This event highlights Helus Pharma's ongoing efforts to innovate in mental health therapies and engage with investors and the healthcare community. The session will be webcast live and available for replay on the company's investor relations website.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
